Saturday 17 October 2026 Export ABCL’s income statement to Excel — free account

AbCellera Biologics Inc.

AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 50.0% and free cash flow grew 152.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.80 0.88 −6.94%

Follow ABCL

Alert me

Market cap: $4.1B
P/E: 0.0×
Fwd P/E: −8.7×
Dividend yield: —
F-score: 5/9
Altman Z: 1.66
Beneish M: −1.06
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.68

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	3	—	—	1	—	—	4	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 17.01%

Capital & Financial Ratios $m

Market Cap 4,110.00

Revenue 66.17

Net Income (164.66)

Free Cash Flow (119.67)

Net Debt (565.10)

Current Ratio 12.77

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (8.68)

P/S ratio 54.49

P/B ratio 4.02

Past 5Y EPS Growth —

This Y EPS Growth (35.44%)

Next Y EPS Growth (9.58%)

Next Y revenue growth (64.90%)

Next 5Y EPS Growth (18.95%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 98.28%

10-year low 10-year high

P/B against its own 10 years 80.65%

10-year low 10-year high

EV/Sales against its own 10 years 98.25%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	786	651	559	565
Receivables	31	34	58	19
Inventory	—	—	—	—
Other	56	67	111	96
	872	751	728	679

	2023	2024	2025	Q'26
Payables	50	55	51	32
ST’ Debt	—	—	—	—
Other	—	—	—	—
	119	77	64	53

Compound Annual Growth %

	10y	5y	3y
Sales	—	(20.27%)	(46.31%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	3.09%	(7.79%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	8	4	—	—	—
’25	4	17	9	45	75
’24	10	7	7	5	29
’23	12	10	7	9	38
’22	317	46	101	22	485
’21	203	28	6	139	375
’20	5	11	9	208	233

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(34)	26	—	—	—
’25	(12)	(32)	(53)	(35)	(131)
’24	(42)	(30)	(29)	(8)	(109)
’23	(44)	20	0	(20)	(44)
’22	100	273	(127)	31	277
’21	110	158	(6)	(17)	245
’20	(1)	26	(4)	1	23

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(37)	24	—	—	—
’25	(22)	(46)	(62)	(45)	(174)
’24	(66)	(50)	(47)	(24)	(187)
’23	(59)	(7)	(21)	(35)	(121)
’22	86	242	(141)	19	205
’21	106	121	(15)	(26)	186
’20	(6)	22	(8)	0	8

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.14)	(0.18)	—	—	—
’25	(0.15)	(0.12)	(0.19)	(0.03)	(0.49)
’24	(0.14)	(0.13)	(0.17)	(0.11)	(0.55)
’23	(0.14)	(0.11)	(0.10)	(0.17)	(0.51)
’22	0.54	(0.02)	0.08	(0.10)	0.50
’21	0.37	(0.01)	(0.08)	0.19	0.48
’20	(0.01)	0.03	(0.02)	0.46	0.45

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	37.62	12.20	5.42	3.87	2.34	1.89	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	71.91	55.22	14.97	11.38	6.06	6.52
People
People	Employees	—	—	—	—	206	386	495	586	596	562
	Revenue/emp, $m	—	—	0.00	0.00	1.13	0.97	0.98	0.06	0.05	0.13
Income, $m
Income, $m	Revenue	—	—	9	12	233	375	485	38	29	75
	Gross margin, %	—	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	0	(2)	158	219	239	(174)	(200)	(178)
	EBT margin, %	—	—	3.50	(19.04)	67.69	58.41	49.26	(457.67)	(695.02)	(236.39)
	Net income	—	0	0	(2)	119	153	159	(146)	(163)	(146)
	Depreciation	—	—	1	2	5	17	33	31	97	29
Per share, $
Per share, $	Revenue	—	—	0.06	0.08	1.46	1.36	1.70	0.13	0.10	0.25
	Earnings	—	—	0.00	(0.01)	0.53	0.56	0.56	(0.51)	(0.55)	(0.49)
	Cash flow	—	—	0.02	0.02	0.14	0.89	0.97	(0.15)	(0.37)	(0.44)
	Capex	—	—	(0.04)	(0.03)	(0.09)	(0.21)	(0.25)	(0.27)	(0.27)	(0.14)
	Free cash flow	—	—	(0.01)	(0.01)	0.05	0.68	0.72	(0.42)	(0.64)	(0.58)
	Book value	—	—	0.00	0.07	5.22	3.72	4.33	3.99	3.59	3.24
	Shares, m	—	—	149	151	159	276	285	289	294	299
Valuation, ×
Valuation, ×	P/E	—	—	5,890.00	5,890.00	53.87	26.00	16.95	0.00	0.00	0.00
	P/S	—	—	0.00	0.00	27.48	10.51	5.57	43.57	29.91	13.60
	P/B	—	—	1,287.81	1,287.81	7.71	3.84	2.19	1.44	0.82	1.06
	EV/Sales	—	—	0.00	0.00	24.94	8.53	3.70	23.01	7.46	6.21
	EV/FCF	—	—	747.79	747.79	725.38	17.19	8.78	(7.06)	(1.13)	(2.63)
Cash, $m
Cash, $m	Operating cash flow	—	—	4	3	23	245	277	(44)	(109)	(131)
	Capex	—	—	(5)	(4)	(15)	(58)	(73)	(78)	(78)	(43)
	Free cash flow	—	—	(2)	(1)	8	186	205	(121)	(187)	(174)
Balance, $m
Balance, $m	Working capital	—	—	9	5	710	809	907	753	675	664
	Total debt	—	—	4	3	7	40	83	—	—	—
	Net debt	—	—	(6)	(4)	(594)	(748)	(911)	(786)	(651)	(559)
	Shareholders’ equity	—	—	—	10	831	1,026	1,233	1,152	1,056	967
Returns, %
Returns, %	ROA	—	—	0.00	(18.83)	16.54	13.21	11.09	(9.67)	(11.43)	(10.78)
	ROIC	—	—	0.00	(41.89)	41.25	46.00	42.05	(40.43)	(48.52)	(33.25)
	ROE	—	—	8.34	(65.94)	20.43	16.53	14.03	(12.27)	(14.75)	(14.47)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DFTX Definium Therapeutics, Inc.	$4.6B	— (loss-making)	—	—	n/m	−78.31% (below 0%: shrinking)	0.00%	0.00%	Compare
DNTH Dianthus Therapeutics, Inc.	$4.2B	— (loss-making)	— (loss-making)	+294.30% (above 0%: growing)	n/m	−105.37% (below 0%: shrinking)	100.00%	(8,079.11%)	Compare
EWTX Edgewise Therapeutics, Inc.	$4.2B	— (loss-making)	—	—	n/m	−30.24% (below 0%: shrinking)	0.00%	0.00%	Compare
ABCL AbCellera Biologics Inc.	$4.1B	— (loss-making)	— (loss-making)	−76.29% (below 0%: shrinking)	n/m	+151.98% (above 0%: growing)	100.00%	(1,550.05%)
LEGN Legend Biotech Corporation Sponsored ADR	$3.8B	— (loss-making)	112×	+51.90% (above 0%: growing)	n/m	−26.79% (below 0%: shrinking)	64.54%	14.37%	Compare
TNGX Tango Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−4.58% (below 0%: shrinking)	0.00%	0.00%	Compare
RLAY Relay Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−95.44% (below 0%: shrinking)	n/m	+2.13% (above 0%: growing)	100.00%	(25,949.71%)	Compare
ARQT Arcutis Biotherapeutics, Inc.	$3.7B	131×	196×	+59.33% (above 0%: growing)	n/m	+227.96% (above 0%: growing)	91.58%	12.65%	Compare
TLX Telix Pharmaceuticals Limited	$3.6B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
Median of peers	$3.8B	—	—	+51.90%	—	−28.51%	64.54%	0.00%

All 614 Biotechnology stocks →

AbCellera Biologics Inc. (ABCL) key facts

Strength: AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
AbCellera Biologics Inc. (ABCL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ABCL traded at $11.80, a market capitalization of $4.1 billion.
Return on equity was −14.5% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.66 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.